The present invention relates to a contrast agent for nuclear magnetic resonance imaging, and more particularly, to a contrast agent for nuclear magnetic resonance imaging containing melanin nanoparticles having a uniform shape and size, thereby providing good dispersibility in water, no cell toxicity, and a long retention time in vivo.

Disclosed is CT or MR contrast agent which comprises a base or carrier scaffold formed of a polyhydroxol compound having a linker to which a Gd-DOTA is covalently bonded. Also disclosed is a method of screening a patient for colon cancer using a CT or MR contrast, which method comprises administering to a patient undergoing screening a compound as above described.

A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.

A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.

Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.

The invention relates to a statistical polysaccharide with a weight-average molecular weight of between 100 kDa and 1000 kDa of the following formula (I): in which: each Rc independently represents a group containing a chelating agent, each Z independently represents a binder which may be a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said chain able to be either linear or branched and being able to contain one or more unsaturations and being able to contain one or more heteroatoms, preferably chosen from nitrogen, oxygen, sulfur and atoms of the halogen family, x is between 0.005 and 0.7, preferably between 0.05 and 0.7, and preferentially between 0.2 and 0.6, y is between 0.01 and 0.7, preferably between 0.05 and 0.2, the ratio of y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, and the sum of x+y being greater than or equal to 0.30, preferably greater than or equal to 0.35. The invention also relates to the use of said polysaccharide in a dialysis process in order to capture at least one metal, in an MRI imaging process, in a brachytherapy process or in a process for marking foodstuffs to prevent forgeries.

Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T.sub.1 contrast enhancement (T.sub.1˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.

Disclosed is a composition of a polarization source dispersed in an aqueous medium. Preferably, the polarization source forms a composite with a host. As the aqueous medium, a hydrogel is also usable in addition to water.

Disclosed is a composition of a polarization source dispersed in an aqueous medium. Preferably, the polarization source forms a composite with a host. As the aqueous medium, a hydrogel is also usable in addition to water.

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T.sub.1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T.sub.1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. .sup.86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.